New Hope

New Hope Biotech is a clinical-stage biotechnology company based in Guangzhou, China, dedicated to the development of innovative cell therapies for cancer. The company leverages its proprietary CAR-T and TCR-T platforms to engineer immune cells that can effectively target and eliminate both liquid and solid tumors. Its lead candidate, NH-101, is a CD19-targeted CAR-T therapy currently in clinical development for B-cell malignancies. Additionally, the company is advancing a robust pipeline of next-generation therapies, including BCMA-targeted CAR-T for multiple myeloma and Claudin 18.2-targeted therapies for gastric and pancreatic cancers. New Hope Biotech aims to address unmet medical needs in oncology through advanced genetic engineering and cell manufacturing technologies.